Quest Laboratories LimitedQUESTLABCorporate

Pharmaceuticals - Indian - Formulations Latest results: Mar 2026 8 quarters of data

₹94.00

MCap ₹154 Cr · P/E 9.4

Quest Laboratories Limited — Stock analysis & AI research Quest Laboratories Limited — Multibagger AI analysis Quest Laboratories Limited — Seasonality — best & worst months Quest Laboratories Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹32 Cr

Sales · Mar 2026

-30.2% YoY

₹4 Cr

Operating Profit · Mar 2026

+411.1% YoY

12.8%

OPM % · Mar 2026

+652.9% YoY

₹3 Cr

Net Profit · Mar 2026

+47.9% YoY

₹1.75

EPS · Mar 2026

+48.3% YoY

📝 Quest Laboratories Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Quest Laboratories Limited reported revenue of ₹32 crore for the quarter ended March 2026 (Q4 FY26), down 30.2% from ₹46 crore in the same quarter last year, and up 5.8% sequentially over the December 2025 quarter.

Net profit rose 47.9% year-on-year to ₹3 crore, from ₹2 crore. Earnings per share (EPS) came in at ₹1.75.

Operating profit stood at ₹4 crore — an operating margin (OPM) of 12.8%, compared with 1.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Quest Laboratories Limited posted revenue of ₹150 crore, a growth of 25.8% over FY25, with a net profit of ₹16 crore (up 34.9% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹150 crore with a net profit of ₹16 crore.

Valuation snapshot

At the current price of ₹94.00, QUESTLAB has a market capitalisation of ₹154 crore and a trailing P/E of about 9.4.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 15th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 66.78%, foreign institutional investors (FIIs) 0.61%, domestic institutional investors (DIIs) 2.04%, public shareholders 30.56% of Quest Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹154 Cr

Current Price ?

₹94.0

P/E ?

9.35below ind

Industry P/E ?

21.30

P/B ?

1.60

P/S ?

1.03

P/FCF ?

-9.63

Enterprise Value ?

₹162 Cr

EV/EBITDA ?

8.51

PEG ?

0.21

Earnings Yield ?

11.2%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹150 Cr

OPM ?

12.7%

Profit after tax (TTM) ?

₹16 Cr

EPS (TTM) ?

₹10.05

ROCE ?

18.0%

ROE ?

17.2%

ROA ?

14.8%

Growth

Sales — latest qtr ?

₹32 Cr

PAT — latest qtr ?

₹3 Cr

YoY qtr sales growth ?

-30.2%

YoY qtr profit growth ?

47.9%

Sales growth (3y) ?

22%

Sales growth (5y) ?

30%

Profit growth (3y) ?

44%

Profit growth (5y) ?

87%

Financial Health

Debt ?

₹8 Cr

Debt to Equity ?

0.08

Interest Coverage ?

11.2

Current Ratio ?

N/A

Ownership

Promoter holding ?

66.78%

Change in promoter holding ?

0.57%

Pledged percentage ?

N/A

Market

Return 3 months ?

-0.5%

Return 6 months ?

-26.0%

🗓️ Quarterly results (8 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	YoY %	QoQ %
Sales	15	43	15	46	61	26	31	32	-30.2%	+5.8%
Operating Profit	2	11	1	1	5	3	7	4	+411.1%	-40.1%
Other Income	0	1	0	3	3	1	1	-1	-138.4%	-329.1%
Interest	0	1	0	0	0	1	0	0	-56.8%	-66.2%
Depreciation	0	0	0	0	0	0	0	0	+10.5%	+2.5%
Profit Before Tax	2	11	1	4	7	4	7	2	-32.8%	-63.8%
Net Profit	1	8	1	2	6	4	4	3	+47.9%	-28.7%
EPS	0.90	4.89	0.48	1.18	3.39	2.45	2.46	1.75	+48.3%	-28.9%
OPM %	11.7%	26.7%	4.4%	1.7%	7.5%	13.2%	22.6%	12.8%	+652.9%	-43.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹119 Cr	₹150 Cr	₹150 Cr	+25.8%
Operating Profit	₹15 Cr	₹19 Cr	₹19 Cr	+30.3%
OPM %	12.26%	12.70%	12.70%	+3.6%
NPM %	10.24%	10.99%	10.99%	+7.3%
Other Income	₹5 Cr	₹4 Cr	₹4 Cr	-12.9%
Depreciation	₹1 Cr	₹1 Cr	₹1 Cr	+21.6%
Interest	₹1 Cr	₹2 Cr	₹2 Cr	+55.5%
EBIT	₹14 Cr	₹18 Cr	₹18 Cr	+30.8%
PBT	₹17 Cr	₹21 Cr	₹21 Cr	+17.6%
Tax	₹3 Cr	₹5 Cr	₹5 Cr	+33.0%
Net Profit	₹12 Cr	₹16 Cr	₹16 Cr	+34.9%
EPS	₹7.45	₹10.05	₹10.05	+34.9%
Material Cost	₹25 Cr	₹82 Cr	₹82 Cr	+228.6%
Employee Cost	₹2 Cr	₹4 Cr	₹4 Cr	+93.6%
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	1	12	16	16	+0.0%
Reserves	14	17	65	80	+23.1%
Borrowings	4	5	30	8	-73.3%
Other Liabilities	28	27	10	6	-40.0%
Total Liabilities	47	61	122	111	-9.0%
Fixed Assets	10	10	12	15	+25.0%
CWIP	0	0	0	1	—
Investments	0	7	52	16	-69.2%
Other Assets	37	44	58	79	+36.2%
Total Assets	47	61	122	111	-9.0%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	4	3	-23	-11	+52.2%
Cash from Investing Activity	-4	-5	-44	35	+179.5%
Cash from Financing Activity	0	2	67	-24	-135.8%
Net Cash Flow	0	0	-0	-0	—
Free Cash Flow	1	2	-27	-16	+40.7%
CFO/OP	72%	46%	-120%	-34%	+71.7%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	118	108	105	118	+12.4%
Inventory Days	97	113	99	163	+64.6%
Days Payable	215	144	26	24	-7.7%
Cash Conversion Cycle	1	77	178	258	+44.9%
Working Capital Days	27	58	72	258	+258.3%
ROCE %	47%	57%	27%	18%	-33.3%

👥 Shareholding (latest 4 periods)

Metric	Mar 2025	Sep 2025	Dec 2025	Mar 2026	% Chg
Promoters	66.21%	66.78%	66.78%	66.78%	+0.0%
FIIs	0.95%	0.93%	0.61%	0.61%	+0.0%
DIIs	2.07%	1.39%	1.37%	2.04%	+48.9%
Public	30.77%	30.89%	31.24%	30.56%	-2.2%
No. of Shareholders	1,001	1,084	1,017	911	-10.4%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SHILPAMED Shilpa Medicare	₹1,032.00	20,184	67.5	1,683	297	28.4%	17.7%	47.7%	454.9%	44.9%	115.2%
2	MARKSANS Marksans Pharma	₹332.50	15,068	29.1	3,171	521	22.5%	16.4%	12.5%	9.7%	35.6%	174.8%
3	BLISSGVS Bliss GVS	₹680.50	7,236	52.9	1,005	142	19.7%	14.1%	14.4%	48.7%	37.6%	15.8%
4	JSLL Jeena Sikho	₹507.55	6,309	26.7	852	236	42.6%	27.7%	17.1%	85.5%	28.8%	28.0%
5	SENORES Senores Pharmaceuticals	₹1,327.50	6,114	46.6	692	131	29.5%	19.0%	63.0%	108.7%	30.6%	43.8%
6	WINDLAS Windlas Biotech	₹1,129.50	2,331	35.7	942	66	11.1%	7.1%	18.9%	9.0%	18.1%	-0.1%
7	VENUSREM Venus Remedies	₹1,651.10	2,210	19.0	811	117	20.4%	14.4%	17.9%	127.9%	35.6%	139.3%
8	SYNCOMF Syncom Formulations	₹23.44	2,203	1.3	12,547	1,729	15.2%	13.8%	2566.9%	3386.8%	7.4%	57.7%
9	HESTERBIO Hester Biosciences	₹2,187.90	1,861	13.6	318	137	30.8%	43.0%	4.7%	101.2%	-8.4%	460.8%
10	AMRUTANJAN Amrutanjan Health	₹489.00	1,413	26.2	512	54	14.4%	10.5%	11.0%	1.3%	9.5%	-45.4%
11	LINCOLN Lincoln Pharmaceuticals	₹601.50	1,205	12.5	694	97	14.6%	14.0%	7.6%	7.2%	15.1%	30.9%
12	BAFNAPH Bafna Pharmaceuticals	₹301.45	713	91.6	143	8	8.2%	5.5%	3.3%	166.8%	-23.2%	-97.8%
13	KILITCH Kilitch Drugs	₹198.00	692	16.1	237	29	15.3%	12.3%	18.7%	20.1%	4.0%	-13.0%
14	MEDICAMEQ Medicamen Biotech	₹323.80	439	1.3	9,516	381	10.1%	4.0%	5751.8%	3308.0%	11.3%	15.3%
15	QUESTLAB Quest Laboratories	₹137.50	225	13.7	150	16	12.7%	11.0%	25.8%	34.9%	-30.2%	47.9%
16	JFLLIFE Jfl Life	₹51.05	168	24.7	131	7	9.1%	5.2%	60.2%	53.1%	-4.2%	48.5%
17	ZENITHDRUG Zenith	₹78.45	135	41.7	171	4	7.0%	2.3%	—	—	40.9%	100.0%
18	ALPA Alpa Laboratories	₹62.32	131	29.6	111	4	1.7%	4.0%	-5.9%	-22.5%	25.2%	-91.7%
19	MEDIORG Medicamen	₹101.45	119	—	22	-3	-12.9%	-14.0%	—	—	-77.5%	-383.0%
20	BIOFILCHEM Biofil Chemicals	₹33.13	54	110.4	34	0	2.3%	1.4%	-15.0%	405.5%	92.1%	-95.5%

❓ Frequently asked questions

What was Quest Laboratories Limited's revenue in Q4 FY26?

What was Quest Laboratories Limited's net profit in Q4 FY26?